Utility of FibroScan-based scoring systems to narrow the risk group of nonalcoholic fatty liver disease with comorbidities

Table 3 Sensitivity, specificity, positive predictive value, and negative predictive value of each score and marker (L-I vs H)

	FIB-4		FAST		Agile 3+		Agile 4		LSM		M2BPGi
Risk	L-I	H	L-I	H	L-I	H	L-I	H	L-I	H	L-I	H
n	122	69	146	45	111	80	148	43	136	55	148	43
HCC	3	23	18	8	0	26	12	14	10	16	11	15
P value	< 0.01		0.35		< 0.01		< 0.01		< 0.01		< 0.01
Sensitivity		0.89		0.31		1		0.54		0.62		0.58
Specificity		0.74		0.89		0.67		0.90		0.82		0.90
PPV		0.35		0.30		0.33		0.45		0.36		0.47
NPV		0.98		0.89		1		0.93		0.93		0.93
EGV	2	23	14	11	0	25	2	23	3	22	4	21
P value	< 0.01		0.01		< 0.01		< 0.01		< 0.01		< 0.01
Sensitivity		0.92		0.44		1		0.92		0.88		0.84
Specificity		0.74		0.88		0.67		0.89		0.82		0.89
PPV		0.34		0.36		0.31		0.56		0.42		0.54
NPV		0.98		0.91		1		0.99		0.98		0.97

EGV: Esophagogastric varices; HCC: Hepatocellular carcinoma; PPV: Positive predictive value; NPV: Negative predictive value; M2BPGi: Mac2-binding protein glycosylation isomer; FAST: FibroScan-AST; FIB-4: Fibrosis-4; LSM: Liver stiffness measurement.